$RXRX News
Last published 13h ago
- 13h agoRXRXRecursion to Participate in Upcoming Investor ConferencesGlobeNewswireSalt Lake City, UT, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced its participation in the following upcoming investor conferences:
- 1w agoRXRXRECURSION PHARMACEUTICALS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 5.02 Item 7.01 Item 9.01
- 1w agoRXRXRecursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as ChairGlobeNewswireNew Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden reductions in FAP, with activity throughout the GI tract and in larger, higher-risk
- 1w agoRXRXNew Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk PolypsGlobeNewswireUpdated TUPELO results featured in a Presidential Plenary at CGA-IGC: Lisa Boardman, M.D., Professor of Medicine at Mayo Clinic, presented updated findings from the Phase 1b/2 TUPELO trial in familial adenomatous
- 1w agoRXRXRecursion Appoints Fred Hassan as Chair of the BoardGlobeNewswireSalt Lake City, UT, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has
- 2w agoRXRXRecursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3GlobeNewswireWebinar will include earnings updates and REC-4881 data as well as KOL and patient panels, presented live from CGA-IGC on Tuesday, November 3, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMTThird quarter 2026 results will
- 3w agoRXRXRecursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their CollaborationGlobeNewswireSalt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding
- 3w agoRXRXRecursion Announces Pricing of $200 Million Underwritten Offering of Class A Common StockGlobeNewswireSalt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding
- 3w agoRXRXRecursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership MilestoneGlobeNewswireLeading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest $200 million in
- 1mo agoRXRXEnveda secures $311M to bring more nature-derived AI drugs into clinical trialsTechCrunch
- 1mo agoTEMRXRXTempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation ModelBusiness WireTempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new agreement under which
- 2mo agoHYFTVEEVILMNCERT+1The Market Just Told You Which Layer Of AI Biology It Is Paying ForGlobeNewswireAUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season in life sciences technology has just delivered an unusually clean verdict. The company that owns the industry’s data
- 3mo agoRXRXRecursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery ProgramGlobeNewswireGenentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for
- 3mo agoRXRXRecursion to Participate in Upcoming Investor ConferencesGlobeNewswireSalt Lake City, UT, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following
- 3mo agoRXRXRecursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesGlobeNewswireSalt Lake City, UT, July 31, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on July 27, 2026, the Compensation
- 3mo agoRXRXRecursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5thGlobeNewswireSalt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) -- Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) – Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives,
- 3mo agoHYFTAMDRXRXABSI+2A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is HeadedPR NewswireAmerican News Group News Commentary - The race to bring artificial intelligence into drug discovery has become one of the most closely watched...
- 4mo agoHYFTTEMABCLSDGR+1As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the DataPR NewswireUSA News Group, There is a growing consensus in artificial intelligence that the models themselves are becoming interchangeable, and that lasting...
- 4mo agoGTBPNKTXFATECMPX+1A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting DrugsPR NewswireDrug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital ...
- 4mo agoHYFTABSIRXRXSDGR+1The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItPR NewswireEquity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a...
- 5mo agoRXRXRecursion to Participate in Upcoming Investor ConferencesGlobeNewswireSalt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming
- 5mo agoRXRXRecursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesGlobeNewswireSalt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation
- 5mo agoRXRXAltitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake CityGlobeNewswireSALT LAKE CITY, May 19, 2026 (GLOBE NEWSWIRE) -- Altitude Lab, the platform-first biotech-startup accelerator founded by Recursion (NASDAQ:RXRX), announced today that its portfolio companies have collectively raised
- 6mo agoBFLYHTFLMBQIFRXRX+1The Future of Intoxication Detection May Be in Your VoiceGlobeNewswireAUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement
- 6mo agoRXRXRecursion Reports First Quarter Financial Results and Provides Business UpdateGlobeNewswireMultiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable,
- 6mo agoRXRXRecursion Announces Board TransitionGlobeNewswireSalt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will
- 6mo agoRXRXRecursion to Report First Quarter 2026 Business Updates and Financial Results on May 6GlobeNewswireSalt Lake City, UT, April 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and
- 7mo agoRXRXRecursion to Participate in Upcoming Investor ConferencesGlobeNewswireSalt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following
- 7mo agoRXRXRecursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech PlatformGlobeNewswireNEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (NASDAQ:RXRX), a
- 7mo agoRXRXRecursion Announces Vicki Goodman, M.D., as Incoming Chief Medical OfficerGlobeNewswireSalt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will
- 8mo agoNVDARXRXTEMNvidia's Bet on Digital Biology and Stocks That Could Ride the WaveGlobeNewswireDENVER, March 16, 2026 (GLOBE NEWSWIRE) -- When Jensen Huang talks about the future of technology, markets tend to listen. After leading NVIDIA (NASDAQ:NVDA) to become one of the most valuable companies in the world
- 8mo agoPACBRXRXPacBio Announces the Appointment of Chris Gibson to the Board of DirectorsGlobeNewswireMENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to
- 8mo agoNXPLRXRXXWELAI Biotech, APAC Expansion, and Balance Sheet Rebuilds Set the Morning ToneGlobeNewswireDENVER, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a strong crosscurrent of AI-powered drug discovery, cross-border biologics distribution, and capital structure resets. From micro-cap transformation
- 8mo agoRXRXRecursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireDelivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical and preclinical
- 8mo agoRXRXRecursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTCGlobeNewswireSalt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes' Lightning
- 8mo agoRXRXRecursion to Participate in Upcoming Investor ConferencesGlobeNewswireSalt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following
- 8mo agoRXRXRecursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25GlobeNewswireSalt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and
- 9mo agoRXRXRecursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesGlobeNewswireSalt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the
- 9mo agoGHILMNKBLBRXRXAI, Genomics, and CRISPR Signal a New Phase of Biological InnovationGlobeNewswireDENVER, Feb. 10, 2026 (GLOBE NEWSWIRE) -- As artificial intelligence continues to move beyond software and automation, its impact on genomics and gene editing is becoming increasingly tangible. Recent developments
- 9mo agoRXRXTEMSDGRLLYAI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural ShiftPR NewswireEquity-Insider.com News Commentary – The global AI medical imaging market exploded to a staggering $2.57 trillion in 2026 as the entire healthcare...
- 11mo agoGTBPERASFHTXOABI+1Platform Technologies Drive $211B Surge in Precision Cancer TreatmentPR NewswireEquity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies...
- 11mo agoRXRXPositive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 WeeksGlobeNewswireREC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks off therapy (week
- 11mo agoRXRXRecursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025GlobeNewswireSalt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical
- 11mo agoANVSAVAINTLARXRX+1Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033GlobeNewswireMarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer focus on
- 1y agoRXRXRecursion Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireAchieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of neurological diseasesWith
- 1y agoRXRXRecursion Announces CEO Transition Plan to Drive Next Phase of GrowthGlobeNewswireSalt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board of Directors has
- 1y agoRXRXRecursion to Participate in Upcoming Investor ConferencesGlobeNewswireSalt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following
- 1y agoRXRXRecursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5thGlobeNewswireSalt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and
- 1y agoNVDAINTCAPLDARM+7Nvidia's $100 billion OpenAI deal showcases chipmaker's growing investment portfolioCNBCThe sheer number of Nvidia's venture and public equity investments shows how central the company has become to the Silicon Valley and AI ecosystems.
- 1y agoRXRXRecursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts